Treating “Treatment-Resistant Depression”: Bringing Hope with Glutamatergic Antidepressants

For patients with treatment-resistant depression (TRD), conventional monoaminergic antidepressants often fall short, leaving clinicians searching for more effective solutions. This session will explore the limitations of traditional antidepressants, including delayed response, nonresponse, and the challenges of TRD. Attendees will examine the mechanisms of action and the latest clinical and real-world data on emerging glutamatergic and neuromodulation therapies, which offer new hope for patients who have struggled with inadequate treatment response. Practical strategies for personalized treatment planning, including shared decision-making, will also be discussed to enhance patient engagement and outcomes. Join us for an insightful discussion on the evolving landscape of TRD treatment.

Supported by an independent educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC: a Johnson & Johnson Company.